Walvax Biotechnology Co's Total Assets for the quarter that ended in Mar. 2024 was ¥15,387 Mil.
During the past 12 months, Walvax Biotechnology Co's average Total Assets Growth Rate was -3.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 13.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 23.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 9.60% per year.
During the past 13 years, Walvax Biotechnology Co's highest 3-Year average Total Assets Growth Rate was 114.50%. The lowest was -4.70%. And the median was 29.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Walvax Biotechnology Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Walvax Biotechnology Co (SZSE:300142) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Walvax Biotechnology Co's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Walvax Biotechnology Co Total Assets Related Terms
Thank you for viewing the detailed overview of Walvax Biotechnology Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Walvax Biotechnology Co (SZSE:300142) Business Description
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300142 has been successfully added to your 